Research Comparison
DSIP (Delta Sleep-Inducing Peptide) vs PT-141 (Bremelanotide)
A side-by-side research comparison of DSIP (Delta Sleep-Inducing Peptide) and PT-141 (Bremelanotide) drawn from Cobalt Peptides' peptide database records.
DSIP (Delta Sleep-Inducing Peptide)
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide originally isolated from the brain in 1974, composed of nine amino acids. It was initially identified for its role in promoting delta-wave (deep) sleep, but subsequent research has revealed broader neuromodulatory effects, including stress regulation, endocrine modulation, and potential analgesic properties. Despite decades of investigation, its precise mechanisms remain incompletely understood. However, DSIP is widely studied for its ability to enhance sleep architecture without traditional sedative effects, making it of interest in sleep optimization, recovery, and neuroendocrine regulation.
PT-141 (Bremelanotide)
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist with selectivity for the MC3 and MC4 receptors in the central nervous system. Its described mechanism is central rather than vascular, which distinguishes it from compounds acting on peripheral blood flow such as PDE5 inhibitors. A licensed medicine containing bremelanotide exists in some jurisdictions and is prescribed by clinicians; the material supplied here is a research compound and is not that medicine.